477 related articles for article (PubMed ID: 26233890)
41. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.
Pal I; Mandal M
Acta Pharmacol Sin; 2012 Dec; 33(12):1441-58. PubMed ID: 22983389
[TBL] [Abstract][Full Text] [Related]
42. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
Hao P; Kang B; Li Y; Hao W; Ma F
Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
[TBL] [Abstract][Full Text] [Related]
43. Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway.
Jiang H; Shi QQ; Ge LY; Zhuang QF; Xue D; Xu HY; He XZ
Cancer Med; 2019 Aug; 8(10):4836-4844. PubMed ID: 31274247
[TBL] [Abstract][Full Text] [Related]
44. Tumor Protein D52 (TPD52) Inhibits Growth and Metastasis in Renal Cell Carcinoma Cells Through the PI3K/Akt Signaling Pathway.
Zhao Z; Liu H; Hou J; Li T; Du X; Zhao X; Xu W; Xu W; Chang J
Oncol Res; 2017 May; 25(5):773-779. PubMed ID: 27983909
[TBL] [Abstract][Full Text] [Related]
45. Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN/PI3K/AKT pathway.
Wang T; Chen Z; Chen H; Yu X; Wang L; Liu X
J Ethnopharmacol; 2022 Apr; 288():115020. PubMed ID: 35066068
[TBL] [Abstract][Full Text] [Related]
46. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
47. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
48. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men.
Ribback S; Cigliano A; Kroeger N; Pilo MG; Terracciano L; Burchardt M; Bannasch P; Calvisi DF; Dombrowski F
Oncotarget; 2015 May; 6(15):13036-48. PubMed ID: 25948777
[TBL] [Abstract][Full Text] [Related]
49. The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA; Arteaga CL
Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
[TBL] [Abstract][Full Text] [Related]
50. KIR2DL4 promotes the proliferation of RCC cell associated with PI3K/Akt signaling activation.
Ding XF; Chen J; Ma HL; Liang Y; Wang YF; Zhang HT; Li X; Chen G
Life Sci; 2022 Mar; 293():120320. PubMed ID: 35063466
[TBL] [Abstract][Full Text] [Related]
51. Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→︀AKT→︀GSK3β→︀AM signaling.
Chen Y; Li C; Xie H; Fan Y; Yang Z; Ma J; He D; Li L
Oncogene; 2017 May; 36(20):2879-2888. PubMed ID: 28114284
[TBL] [Abstract][Full Text] [Related]
52. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
[TBL] [Abstract][Full Text] [Related]
53. Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway.
Zhou WM; Wu GL; Huang J; Li JG; Hao C; He QM; Chen XD; Wang GX; Tu XH
Cell Signal; 2019 Apr; 56():1-14. PubMed ID: 30465826
[TBL] [Abstract][Full Text] [Related]
54. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors.
Yu K; Lucas J; Zhu T; Zask A; Gaydos C; Toral-Barza L; Gu J; Li F; Chaudhary I; Cai P; Lotvin J; Petersen R; Ruppen M; Fawzi M; Ayral-Kaloustian S; Skotnicki J; Mansour T; Frost P; Gibbons J
Cancer Biol Ther; 2005 May; 4(5):538-45. PubMed ID: 15846106
[TBL] [Abstract][Full Text] [Related]
55. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer.
Akbarzadeh M; Mihanfar A; Akbarzadeh S; Yousefi B; Majidinia M
Life Sci; 2021 Nov; 285():119984. PubMed ID: 34592229
[TBL] [Abstract][Full Text] [Related]
56. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Elfiky AA; Aziz SA; Conrad PJ; Siddiqui S; Hackl W; Maira M; Robert CL; Kluger HM
J Transl Med; 2011 Aug; 9():133. PubMed ID: 21834980
[TBL] [Abstract][Full Text] [Related]
57. Protease-activated receptor 2 enhances renal cell carcinoma cell invasion and migration via PI3K/AKT signaling pathway.
Sun Z; Cao B; Wu J
Exp Mol Pathol; 2015 Jun; 98(3):382-9. PubMed ID: 25773677
[TBL] [Abstract][Full Text] [Related]
58. Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.
Cho D
Cancer J; 2013; 19(4):311-5. PubMed ID: 23867512
[TBL] [Abstract][Full Text] [Related]
59. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents.
Sun H; Wang Z; Yakisich JS
Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890
[TBL] [Abstract][Full Text] [Related]
60. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions.
Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Pirsalehi A; Safaroghli-Azar A; Zali MR; Bashash D
Eur J Pharmacol; 2021 May; 898():173983. PubMed ID: 33647255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
